ATHE Valuation

Alterity Therapeutics Ltd

Add to Watchlist

Advanced Chart

4.940

-0.082(-1.633%)1D

Overview
Forecast
Valuation
Earnings

ATHE Relative Valuation

ATHE's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ATHE is overvalued; if below, it's undervalued.

Historical Valuation

Alterity Therapeutics Ltd (ATHE) is now in the Undervalued zone, suggesting that its current forward PS ratio of 23.08 is considered Undervalued compared with the five-year average of -18.81. The fair price of Alterity Therapeutics Ltd (ATHE) is between 11.60 to 14.08 according to relative valuation methord. Compared to the current price of 5.02 USD , Alterity Therapeutics Ltd is Undervalued By 56.69%.

Relative Value

Fair Zone

11.60-14.08

Current Price：5.02

56.69%

Undervalued

-5.88

Trailing

Forward

-6.44

EV/EBITDA

Alterity Therapeutics Ltd. (ATHE) has a current EV/EBITDA of -6.44. The 5-year average EV/EBITDA is -0.60. The thresholds are as follows: Strongly Undervalued below -3.52, Undervalued between -3.52 and -2.06, Fairly Valued between 0.86 and -2.06, Overvalued between 0.86 and 2.31, and Strongly Overvalued above 2.31. The current Forward EV/EBITDA of -6.44 falls within the Strongly Undervalued range.

-6.10

EV/EBIT

Alterity Therapeutics Ltd. (ATHE) has a current EV/EBIT of -6.10. The 5-year average EV/EBIT is -1.14. The thresholds are as follows: Strongly Undervalued below -4.54, Undervalued between -4.54 and -2.84, Fairly Valued between 0.56 and -2.84, Overvalued between 0.56 and 2.26, and Strongly Overvalued above 2.26. The current Forward EV/EBIT of -6.10 falls within the Strongly Undervalued range.

27.02

Alterity Therapeutics Ltd. (ATHE) has a current PS of 27.02. The 5-year average PS is 9.94. The thresholds are as follows: Strongly Undervalued below -4.34, Undervalued between -4.34 and 2.80, Fairly Valued between 17.09 and 2.80, Overvalued between 17.09 and 24.23, and Strongly Overvalued above 24.23. The current Forward PS of 27.02 falls within the Strongly Overvalued range.

-6.67

P/OCF

Alterity Therapeutics Ltd. (ATHE) has a current P/OCF of -6.67. The 5-year average P/OCF is -2.36. The thresholds are as follows: Strongly Undervalued below -6.27, Undervalued between -6.27 and -4.31, Fairly Valued between -0.41 and -4.31, Overvalued between -0.41 and 1.54, and Strongly Overvalued above 1.54. The current Forward P/OCF of -6.67 falls within the Strongly Undervalued range.

-6.66

P/FCF

Alterity Therapeutics Ltd. (ATHE) has a current P/FCF of -6.66. The 5-year average P/FCF is -2.69. The thresholds are as follows: Strongly Undervalued below -9.40, Undervalued between -9.40 and -6.05, Fairly Valued between 0.66 and -6.05, Overvalued between 0.66 and 4.02, and Strongly Overvalued above 4.02. The current Forward P/FCF of -6.66 falls within the Undervalued range.

Alterity Therapeutics Ltd (ATHE) has a current Price-to-Book (P/B) ratio of 5274.30. Compared to its 3-year average P/B ratio of 896.02 , the current P/B ratio is approximately 488.64% higher. Relative to its 5-year average P/B ratio of 528.73, the current P/B ratio is about 897.54% higher. Alterity Therapeutics Ltd (ATHE) has a Forward Free Cash Flow (FCF) yield of approximately -14.90%. Compared to its 3-year average FCF yield of -63.94%, the current FCF yield is approximately -76.69% lower. Relative to its 5-year average FCF yield of -49.13% , the current FCF yield is about -69.66% lower.

5169.27

P/B

Median3y

896.02

Median5y

528.73

-12.78

FCF Yield

Median3y

-63.94

Median5y

-49.13

Competitors Valuation Multiple

The average P/S ratio for ATHE's competitors is 222.61, providing a benchmark for relative valuation. Alterity Therapeutics Ltd Corp (ATHE) exhibits a P/S ratio of 27.02, which is -87.86% above the industry average. Given its robust revenue growth of %, this premium appears unsustainable.

P/S

P/E

EV/EBITDA

EV/EBIT

P/S

Revenue Growth

Market Cap

ATHE.O

Alterity Therapeutics Ltd

Anebulo Pharmaceuticals Inc

Inovio Pharmaceuticals Inc

1307.31

-100.00%

125.95M

Performance Decomposition

Market capitalization of ATHE increased by 0.00% over the past 1 year. The primary factor behind the change was an decrease in Unknown from 0.00 to 0.00.

The secondary factor is the Unknown, contributed 0.00%to the performance.

Overall, the performance of ATHE in the past 1 year is driven by Unknown.